FDA Approval of Prostate Cancer Imaging Agent a Milestone for Inventor and Johns Hopkins

The U.S. Food and Drug Administration recently approved the first commercially available positron emission tomography (PET) imaging agent targeting the prostate-specific membrane antigen (PSMA). This represents the culmination of 25 years of work for Martin Pomper, M.D., Ph.D., a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Read more about this innovation aquí.